Calls for papers
-
According to Medical Developments International (MVP), the FDA has lifted a clinical hold on MVP’s Penthrox methoxyflurane inhaler and, as a result, MVP is now preparing a Phase 3 trial of Penthrox for trauma pain… Read more . . .
-
Sorrento Therapeutics announced that the FDA has given the company the okay to move ahead with a Phase 1 trial of its Covishield (STI-9199) intranasal antibody cocktail in healthy volunteers. According to Sorrento, in vitro… Read more . . .
-
BlueWillow Biologics and Medigen Vaccine Biologics Corporation (MVC) have announced that a preclinical study of their BW-1019 intranasal COVID-19 booster demonstrated that giving the nasal vaccine after intramuscular vaccination induced neutralizing antibodies and protected against disease in… Read more . . .
-
Non-profit pharma company Harm Reduction Therapeutics (HRT) said that a Phase 1 clinical trial of its HRT001 naloxone nasal spray in healthy volunteers met its primary endpoint, demonstrating the bioequivalence of a 3.0 mg dose… Read more . . .
-
Broughton, a CRO that offers development and analysis of inhaled drugs, especially nicotine and cannabinoid products, has announced the establishment of a US subsidiary. Tony Jones, who has most recently been Senior Managing Health Scientist… Read more . . .
-
DPI developer Pulmatrix has hired Margaret Wasilewski as its Chief Medical Officer, the company said. Wasilewski most recently offered consulting services as President of ID Remedies, and her previous experience includes clinical development positions at… Read more . . .
-
TFF Pharmaceuticals has partnered with CDMO Catalent for scale-up and manufacturing of dry powder formulations based on TFF’s thin film freezing technology the companies have announced. The partnership will make the TFF technology available to… Read more . . .
-
The Journal of Aerosol Medicine and Pulmonary Drug Delivery, the official journal of the International Society for Aerosols in Medicine (ISAM), has announced that GSK VP US Medical and Therapy Head for Respiratory Thomas G.… Read more . . .
-
The COPD Foundation has partnered with ENA Respiratory for development of ENA’s INNA-051 pegylated TLR2/6 agonist pan-antiviral nasal spray in patients with chronic lung disease, the company said. In June 2021, ENA Respiratory announced that… Read more . . .
-
CDMO Kindeva Drug Delivery has announced that it will invest in a second MDI manufacturing line capable of filling lower global warming potential (GWP) propellants such as HFA 152a and HFO 1234ze in response to… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
December 9-December 11: DDL 2026, Edinburgh, Scotland
April 27-30: RDD Europe 2027, Antibes, France
May 12-13: USP Joint Workshop: Quality and Product Performance Testing of Orally Inhaled and Nasal Drug Products, Rockville, MD, USA
June 30: RespireX 2027, Boston, MA, USA